Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimodivir + Oseltamivir in Hospitalized Influenza A
NCT02532283Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial in Influenza A infection comparing JNJ-63623872 plus Oseltamivir with Placebo plus Oseltamivir (2 arms). Primary endpoints: Maximum Observed Plasma Concentration of Pimodivir at Day 3, Minimum Observed Plasma Concentration of Pimodivir at Day 3 and 1 more. Started Dec 2015; status: completed.
02
Drugs
pimodivir
03
Conditions
Influenza A infection
Beyond the preview
Go deeper on NCT02532283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02532283.